One of the therapeutic hallmarks of the ongoing (COVID-19) pandemic has been the different iterations of successful and sometimes unsuccessful attempts at re-purposing of drugs with pre-existing market authorization for use in COVID-19 patients. We therefore read with interest Perricone et al's., recent report on the clinical outcomes of hospitalized COVID-19 patients exposed to colchicine [1]. This randomized controlled clinical trial (RCT) evaluating efficacy and safety of generic colchicine found no significant difference in the primary composite endpoints of intensive care admissions (ICU) and the need for mechanical ventilation between patients exposed to colchicine added to standard of care (N = 77) vs.